Biohaven nearing the finish line with migraine med Zydis

|About: Biohaven Pharmaceutica... (BHVN)|By:, SA News Editor

Biohaven Pharmaceutical Holding Company (NYSE:BHVN) expects to file its U.S. marketing application next quarter for Zydis (rimegepant), both tablet and oral dissolving tablet formulations, for the acute treatment of migraine.

It recently recently met with the FDA to review the contents of its planned submission and the agency indicated that it appeared to be complete enough for review.

Subscribe for full text news in your inbox